drugset
drugset / Trial / NCT01597310

Dexpramipexole and Warfarin Drug Drug Interaction (DDI) Study

NCT01597310 ↗

Phase 1 Completed 15 enrolled Knopp Biosciences
Non-randomizedParallel-groupOpen-labelBasic science

Summary

This study will assess the effect of dexpramipexole on the pharmacokinetics (PK) of the CYP2C9 probe substrate warfarin in healthy volunteers.

Timeline

Start
2012-05
Primary completion
2012-07
Completion
2012-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Dexpramipexole Small molecule 150 mg —
Subject Warfarin Small molecule 25 mg —

Indications

No indication recorded.